etanercept Archives - Rothwell Figg BiosimilarIP Blog

Posted in:
Regulatory

Another Biosimilar Receives FDA Approval and Is Confronted with Litigation
By Benjamin R. Holt June 4, 2019 Comments are off
On April 25, 2019, the U.S. Food and Drug Administration (“FDA”) approved new biosimilar product EticovoTM (etanercept-ykro) by...

Read more

Tagged with: aBLA, Amgen, BPCIA, Enbrel®, etanercept, Eticovo, FDA, Featured, Patent Dance, Regulatory, Samsung Bioepis, Sandoz

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard
By C. Nichole Gifford and Benjamin R. Holt November 14, 2018 Comments are off
RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...

Read more

Tagged with: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Regulatory

The Impact of Biosimilars on Global Pharmaceutical Markets
By Andrew Storaska August 17, 2017 Comments are off
Biologic drugs are quickly reshaping the pharmaceutical landscape as they dominate the drug market in annual sales revenue. Abbvie’s...

Read more

Tagged with: adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, European Commission, Herceptin®, Humira®, Infliximab, Neulasta®, pegfilgrastim, Remicade®, Rituxan®, Rituximab, trastuzumab

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus